Scientists have cloned embryos for the first time from patients with serious diseases and injuries. The research at Seoul National University in South Korea demonstrates the principle of �therapeutic cloning� producing stem cells genetically identical to the patient, which could repair any damaged or diseased tissue.
Two entries ago, I pointed out that Francis Fukuyama's ideas about limits on third-world pharmaceutical trials, reported in the Washington Post, were largely contradicted by a story running the same day in USA Today.
Now, his prediction that "the number of people who are going to want to take the risk [of human cloning] is going to be awfully small" has been shown as similarly naive by South Korea's enthusiastic progress in therapeutic human cloning.
Events haven't just overtaken Fukuyama, they've completely lapped him.